Cosunter(SZ:300436) Xin Lang Cai Jing·2025-09-16 02:48Group 1 - The core viewpoint of the news is that Guangshengtang's stock price has dropped by 5% to 114.57 CNY per share, with a trading volume of 9.67 billion CNY and a turnover rate of 6.00%, resulting in a total market capitalization of 182.47 billion CNY [1] - Guangshengtang Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its main business revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and went public on April 22, 2015, located in Fuzhou, Fujian Province [1] Group 2 - Among the top ten circulating shareholders of Guangshengtang, a fund under China Europe Fund has increased its holdings by 393,100 shares, bringing its total to 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has a current scale of 15.638 billion CNY and has achieved a year-to-date return of 32.89% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 234 days, with the best fund return during this period being 128.39% [3]